Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...
Context will present data highlighting the selection of the first-in-human dose of CT-95, using the minimal anticipated biological effect level (“MABEL”) approach, as required for immune agonist drugs ...
Annual Meeting, taking place in Orlando, Florida, from March 7-11, 2025. Poster Presentation Title: A First-in-Human Phase 1a Randomized, Double-Blind Single-Ascending Dose Study of NAV-240 ...
Copies of the abstract and poster will be available on the AAD online viewing portal beginning at the start of the meeting. Navigator Medicines is a clinical-stage biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results